213 related articles for article (PubMed ID: 19960212)
21. Heredity in Parkinson's disease: new findings.
Lev N; Melamed E
Isr Med Assoc J; 2001 Jun; 3(6):435-8. PubMed ID: 11433638
[TBL] [Abstract][Full Text] [Related]
22. [Transglutaminase and neurodegenerative diseases].
Liu Z; Zeng J; Zeng S; Tang B; Wang J
Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2015 Aug; 32(4):562-6. PubMed ID: 26252108
[TBL] [Abstract][Full Text] [Related]
23. Reduced transglutaminase-catalyzed protein aggregation is observed in the presence of creatine using sedimentation velocity.
Burguera EF; Love BJ
Anal Biochem; 2006 Mar; 350(1):113-9. PubMed ID: 16445883
[TBL] [Abstract][Full Text] [Related]
24. Heat shock proteins reduce alpha-synuclein aggregation induced by MPP+ in SK-N-SH cells.
Fan GH; Zhou HY; Yang H; Chen SD
FEBS Lett; 2006 May; 580(13):3091-8. PubMed ID: 16678164
[TBL] [Abstract][Full Text] [Related]
25. Modulation of neurodegeneration by molecular chaperones.
Muchowski PJ; Wacker JL
Nat Rev Neurosci; 2005 Jan; 6(1):11-22. PubMed ID: 15611723
[TBL] [Abstract][Full Text] [Related]
26. The nuclear proteasome and the degradation of oxidatively damaged proteins.
Voss P; Grune T
Amino Acids; 2007; 32(4):527-34. PubMed ID: 17103119
[TBL] [Abstract][Full Text] [Related]
27. Transglutaminase catalyzes differential crosslinking of small heat shock proteins and amyloid-beta.
Boros S; Kamps B; Wunderink L; de Bruijn W; de Jong WW; Boelens WC
FEBS Lett; 2004 Oct; 576(1-2):57-62. PubMed ID: 15474010
[TBL] [Abstract][Full Text] [Related]
28. Immunoblot analysis reveals that isopeptide antibodies do not specifically recognize the epsilon-(gamma-glutamyl)lysine bonds formed by transglutaminase activity.
Johnson GV; LeShoure R
J Neurosci Methods; 2004 Apr; 134(2):151-8. PubMed ID: 15003381
[TBL] [Abstract][Full Text] [Related]
29. Hsp27 overexpression in the R6/2 mouse model of Huntington's disease: chronic neurodegeneration does not induce Hsp27 activation.
Zourlidou A; Gidalevitz T; Kristiansen M; Landles C; Woodman B; Wells DJ; Latchman DS; de Belleroche J; Tabrizi SJ; Morimoto RI; Bates GP
Hum Mol Genet; 2007 May; 16(9):1078-90. PubMed ID: 17360721
[TBL] [Abstract][Full Text] [Related]
30. Nitric oxide and cellular stress response in brain aging and neurodegenerative disorders: the role of vitagenes.
Calabrese V; Boyd-Kimball D; Scapagnini G; Butterfield DA
In Vivo; 2004; 18(3):245-67. PubMed ID: 15341181
[TBL] [Abstract][Full Text] [Related]
31. [Proteins and mutations: a new vision (molecular) of neurodegenerative diseases].
Christen Y
J Soc Biol; 2002; 196(1):85-94. PubMed ID: 12134639
[TBL] [Abstract][Full Text] [Related]
32. Transglutaminases as possible therapeutic targets in neurodegenerative diseases.
Martin A; De Vivo G; Ricotta M; Iannuzzi M; Gentile V
Recent Pat CNS Drug Discov; 2010 Nov; 5(3):195-202. PubMed ID: 20636272
[TBL] [Abstract][Full Text] [Related]
33. [Stress proteins in medicine].
Sóti C; Nardai G; Csermely P
Orv Hetil; 2003 Mar; 144(13):605-11. PubMed ID: 12728785
[TBL] [Abstract][Full Text] [Related]
34. Immuno-cross reactivity of transglutaminase and cornification marker proteins in the epidermis of vertebrates suggests common processes of soft cornification across species.
Alibardi L; Toni M
J Exp Zool B Mol Dev Evol; 2004 Nov; 302(6):526-49. PubMed ID: 15468051
[TBL] [Abstract][Full Text] [Related]
35. Alpha-synuclein aggregation in neurodegenerative diseases and its inhibition as a potential therapeutic strategy.
Paleologou KE; Irvine GB; El-Agnaf OM
Biochem Soc Trans; 2005 Nov; 33(Pt 5):1106-10. PubMed ID: 16246056
[TBL] [Abstract][Full Text] [Related]
36. Possible physiopathological effects of the transglutaminase activity on the molecular mechanisms responsible for human neurodegenerative diseases.
Iannaccone M; Titta F; Serretiello E; Monfregola M; Gentile V
Recent Pat CNS Drug Discov; 2014; 9(2):76-84. PubMed ID: 25386917
[TBL] [Abstract][Full Text] [Related]
37. Pathogenetic Contributions and Therapeutic Implications of Transglutaminase 2 in Neurodegenerative Diseases.
Liu J; Mouradian MM
Int J Mol Sci; 2024 Feb; 25(4):. PubMed ID: 38397040
[TBL] [Abstract][Full Text] [Related]
38. Tissue transglutaminase in Alzheimer's disease: involvement in pathogenesis and its potential as a therapeutic target.
Wilhelmus MM; de Jager M; Bakker EN; Drukarch B
J Alzheimers Dis; 2014; 42 Suppl 3():S289-303. PubMed ID: 24685636
[TBL] [Abstract][Full Text] [Related]
39. Transglutaminase and diseases of the central nervous system.
Hoffner G; Djian P
Front Biosci; 2005 Sep; 10():3078-92. PubMed ID: 15970562
[TBL] [Abstract][Full Text] [Related]
40. Role of molecular chaperones in neurodegenerative disorders.
Meriin AB; Sherman MY
Int J Hyperthermia; 2005 Aug; 21(5):403-19. PubMed ID: 16048838
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
